Archive · 23 Jul 2025
Syngene International Q1 Profit Soars by 61% to ₹87 Crore
Imagine a company called Syngene, which helps with research.
They made a lot more money this past quarter!
Their profits went up by 61%, reaching ₹87 crore.
They also made more money from what they do, with their total income being ₹875 crore, 11% higher than last year.
The company is doing well partly because they are making their clients, like research companies, stay long term.
They are also expanding and have new facilities starting up.
Everything is going great for the company!
Syngene International's profit after tax grew 61% to ₹87 crore in Q1 FY26.
Revenue from operations increased 11% year-over-year to ₹875 crore.
Operating EBITDA margins reached approximately 24% due to revenue growth and cost optimization.
The growth was attributed to the conversion of pilot programs into longer-term contracts.
Syngene's Human Pharmacology Unit passed a USFDA GCP inspection with no observations.
- Who
- Syngene International.
- What
- Syngene International reported a significant increase in profit and revenue.
- When
- Q1 of FY26.
- Where
- Bengaluru, India and the US.
- Why
- Due to the conversion of pilot programs into longer-term contracts and cost optimization.
- Profit After Tax (Q1 FY26)
- ₹87 crore
- Profit Growth (YoY)
- 61%
- Revenue from Operations
- ₹875 crore
- Revenue Growth (YoY)
- 11%
- Operating EBITDA Margins
- Approximately 24%
- Stock Price (Closing)
- ₹679.65
- Stock Price Change
- 0.5%
- Inspection Result
- USFDA GCP inspection with no observations